The nucleic acid therapeutics market industry is projected to grow from USD Significant by 2032, exhibiting a compound annual growth rate (CAGR) of 10.10% during the forecast period (2023 - 2032). The development of biological products, DNA therapies, and the growth of the pharmaceutical and healthcare industries are all significant market drivers that have propelled the nucleic acid therapeutics market upward.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The demand for nucleic acid-based therapeutics—which correct aberrant gene expression to treat diseases like cancer, sickle cell anemia, cystic fibrosis, Duchenne muscular dystrophy, thalassemia, and others—is primarily driven by the rising prevalence of genetic diseases. For instance, data from the Cystic Fibrosis Foundation released in July 2022 states that 40,000 adults and children in the US have cystic fibrosis (CF). Thus, the market is anticipated to benefit from the high prevalence of cystic fibrosis in the US population. Furthermore, novel therapeutic pharmaceuticals are becoming more readily available in the market as a result of companies' increasing focus on partnerships, collaborations, new product launches, and other initiatives. This might potentially drive the market's expansion. For example, in an effort to improve the treatment efficacy of antisense oligonucleotides in Charcot-Marie-Tooth disease, the CMT Research Foundation and Nanite Inc. joined in February 2023.
Governments, drug manufacturers, and biotechnology businesses are investing more money in nucleic acid-based therapies research and development. This monetary assistance has stimulated creativity and expedited the introduction of novel treatments to the market. Additionally, regulatory bodies like the Food and Drug Administration (FDA) in the United States have streamlined the clearance process for nucleic acid-based medicines and created clear criteria. The expansion of the market has been fueled by these regulatory frameworks, which have incentivized companies to spend in the development of these therapies. Moreover, in the market for nucleic acid therapeutics, cooperation between pharmaceutical corporations, biotechnology businesses, and academic institutions has increased. Partnerships speed up the creation and marketing of new products by facilitating the sharing of information, the pooling of resources, and technological improvements. Thus, driving the nucleic acid therapeutics market revenue.
The US Nucleic Acid Therapeutics market segmentation, based on product includes Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others. The anti-sense oligonucleotides (ASOs) segment dominated the market mostly. Antisense oligonucleotides (ASOs) are single-stranded, short RNA or DNA molecules that can attach themselves to particular messenger RNA (mRNA) sequences and cause the targeted mRNA to either degrade or not translate into a protein. This characteristic renders ASOs a potentially effective treatment approach for a range of ailments, encompassing genetic abnormalities, infectious diseases, and cancer.
The US Nucleic Acid Therapeutics market segmentation, based on application, includes Monogenetic Disorders and Multi-genetic Disorders. The monogenetic disorders category generated the most income because most disorders that are treated with nucleic acid therapies are genetic and quite common. The primary driver of the nucleic acid therapeutics market expansion is the introduction of recently developed and authorized treatments for single gene defects by leading industry players. The top players in the field are concentrating on creating novel approaches to address issues with stability, off-targets, and gene quality in multi-genetic illnesses.
Figure 1: US Nucleic Acid Therapeutics Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The US Nucleic Acid Therapeutics market segmentation, based on end user, includes Hospitals and Clinics and Academic and Research Institutes. The hospitals and clinics category generated the most income. As more treatments and immunizations are used to address a wide range of chronic illnesses, the market for customized pharmaceuticals is growing. This market sector is also being driven by the increasing number of people visiting hospitals and clinics.
The US nucleic acid therapeutics market area will grow at a significant rate because new nucleic acid treatments are becoming more and more approved, and because nucleic acid extraction technology is readily available. The nation's market growth has reached its pinnacle and is anticipated to stay there for the duration of the projection period due to the availability of all positive elements. Additionally, the need for nucleic acid-based therapeutics is rising due to the increasing frequency of autoimmune illnesses in the population, which could boost the market's growth. For example, in June 2022 the Autoimmune Association reported that over 31 million Americans suffer from autoimmune disorders, which are classified as 80–150 distinct chronic conditions. This demonstrates how common autoimmune diseases are in the intended audience.
United States Nucleic Acid Therapeutics Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the nucleic acid therapeutics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, nucleic acid therapeutics industry must offer cost-effective items.
Key Companies in the us nucleic acid therapeutics market include
| Report Attribute/Metric | Details |
| Market Size 2022 | USD XX Billion |
| Market Size 2023 | USD XX Billion |
| Market Size 2032 | USD XX Billion |
| Compound Annual Growth Rate (CAGR) | 10.10% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Application, End User, and Region |
| Countries Covered | US |
| Key Companies Profiled | Benitec Biopharma, Sarpeta Therapeutics, NOVARTIS AG., Agilent Technologies, Protagonist Therapeutics, Qaigen NV, Genzyme Sanofi, Thermo Fisher Scientific, Copernicus, Arbutus Biopharma, Merck KGaA, and Silence Therapeutics |
| Key Market Opportunities | ·      Quick Transition of the Pharmaceutical Sector to Novel Biologics |
| Key Market Dynamics | ·      Increased Frequency of Genetic Disorders ·      Increasing Healthcare Sector Investments |
Frequently Asked Questions (FAQ) :
The US Nucleic Acid Therapeutics market size was valued at USD Significant in 2022.
The market is projected to grow at a CAGR of 10.10% during the forecast period, 2023-2032.
The key players in the market are Benitec Biopharma, Sarpeta Therapeutics, NOVARTIS AG., Agilent Technologies, Protagonist Therapeutics, Qaigen NV, Genzyme Sanofi, Thermo Fisher Scientific, Copernicus, Arbutus Biopharma, Merck KGaA, and Silence Therapeutics.
The Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers category dominated the market in 2022.
The Hospitals and Clinics category had the largest share in the us market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
